Try as we might, we can’t cover all the biotech news out there! This week has brought good news for the fans of bioprinting and neurostimulation devices.
- Synergia Medical, based in Belgium, has raised €8.1M in a Series A round to fund the development of NAOS, a neurostimulation device currently being tested to treat drug-resistant epilepsy.
- Spanish biotech PharmaMar is licensing one of its sea-derived toxic payloads to US-based Seattle Genetics, which will use it to develop antibody-drug conjugates (ADC).
- The AMBER centre in Dublin has partnered with Johnson & Johnson to open a dedicated 3D bioprinting lab.
- Belgian company Bone Therapeutics has completed recruitment of patients with spinal fusion to take part in a Phase IIa trial to test its cell therapy for bone regeneration.
- Sterna biologicals has shown that its enzyme treatment for ulcerative colitis can reduce inflammation in a Phase IIa trial.
- French Genkyotex has shown that its drug GKT831 can efficiently target prostate cancer cells in a preclinical study.
VOJTa Herout, mato181, BlurryMe /Shutterstock